Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans

Table 3 Regression correlation of mRNA expression with clinical traits of aggressive PC in the TCGA cohort: Five candidate genes harbor significant expression associations with aggressive disease traits

Gene	Clinical trait	OR (CIs)	P value	FDR
CCDC115	Disease Free Survival	0.67 (0.53–0.85)	0.0007	0.020
CCDC115	Gleason Score	0.73 (0.58–0.91)	0.0063	0.094
DNAJC10	Tumor Stage	0.67 (0.55–0.81)	0.0001	0.007
	Gleason Score	0.56 (0.44–0.71)	0.0001	0.007
	Disease Free Survival	0.63 (0.46–0.88)	0.0066	0.094
RNF149	Tumor Stage	1.42 (1.12–1.79)	0.0034	0.061
STYXL1	Gleason Score	0.68 (0.55–0.85)	0.0007	0.020
	Tumor Stage	0.69 (0.55–0.86)	0.0009	0.021
	Nodal Metastasis	0.57 (0.40–0.80)	0.0012	0.025
ZNF502	Gleason Score	1.42 (1.16–1.74	0.0006	0.020

ISSN: 1471-2164